Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CURRICULUM VITAE Date Prepared Name July 2015 Lisa M. Schwartz, M.D., M.S. Education Date Institution Degree 1994-1996 Dartmouth College M.S. 1985-1989 New York University School of Medicine M.D. 1981-1985 State University of New York B.A. Postdoctoral Training Date Specialty Institution 1994-1996 General Internal Medicine Fellow Veterans Administration Hospital Dartmouth Medical School 1989-1992 Internal Medicine Residency Bellevue Hospital / NYU Medical Center Licensure and Certification Date Licensure/Certification 1990 National Board of Medical Examiners Parts I, II, III 1992 American Board of Internal Medicine (Recertified 2002, 2012) 1997 Vermont State Medical License #042-000-9475 Curriculum vitae Lisa Schwartz Page 2 Academic Appointments Date Academic Title Institution 2011-Present Co-director, Center for Medicine in the Media The Dartmouth Institute for Health Policy and Clinical Practice Lebanon, NH 2009-Present Professor, Departments of Medicine and Community and Family Medicine. Dartmouth Medical School Hanover, NH 2004-2013 Co-director, VA Outcomes Group VA Medical Center White River Junction, VT 2003-2009 Associate Professor, Departments of Dartmouth Medical School Medicine /Community and Family Medicine Hanover, NH 2003-2005 VA HSR&D Advanced Career Development Awardee VA Medical Center White River Junction, VT 1999-2003 Assistant Professor, Department of Community and Family Medicine Dartmouth Medical School Hanover, NH 1998-2001 VA HSR&D Career Development Awardee VA Medical Center White River Junction, VT 1997-2003 Assistant Professor, Department of Medicine Dartmouth Medical School Hanover, NH 1996-Present Investigator, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, NH 1994-1997 Instructor, Department of Medicine Dartmouth Medical School Hanover, NH 1992-1994 Teaching Assistant New York University School of Medicine, New York, NY Hospital Appointments Date Hospital Title Institution 1994-2013 Staff Physician, Department of Medicine VA Medical Center White River Junction, VT 1992-1994 Primary Care Attending Physician, Department of Medicine Gouverneur Hospital New York, New York 1992-1994 Assistant Attending of Medicine Bellevue Hospital Medical Center New York, NY Curriculum vitae Lisa Schwartz Page 3 Other Professional Positions Date Position Title Institution/Organization 2001-2002 Interim Co-editor Effective Clinical Practice 1998-2001 Associate Editor Co-editor, Special issue -Decision making Effective Clinical Practice (ACP-ASIM peer reviewed journal) 2006-2009 Admissions committee member The Dartmouth Institute for Health Policy and Clinical Practice, Masters Program, Lebanon, NH 2009-2010 Academic, Promotions and Titles Committee Member Dartmouth Medical School 2009-2010 Consultant to Cancer Prevention Division National Cancer Institute 2010-2012 Research Collaboration Agreement FDA 2010-Present Ad-hoc Member Drug Safety and Risk Management Advisory Committee FDA 2011-Present Advisory Board for Enhancing Public Understanding of Science International Collaboration, Oxford, UK 2012-Present Consultation to SEER (Risk communication) National Cancer Institute 2012-Present Steering Committee Member, Preventing Overdiagnosis Co-sponsored by BMJ, Consumer Reports, Dartmouth, University of Oxford, Bond University Australia 2013 Advisory Committee Member (Surovexant) FDA 2013-present Internal AdvisoryBoard 2013-2014 Workshop Steering Committee Collaborator Institute of Medicine's Drug Forum 2014-2015 Consultant Clinicaltrials.gov 2014 Consultant JAMA 2014-present Consultant Brigham & Women's Hospital (Aaron Kessleheim/Jerry Avorn) contract with FDA Dartmouth CTSA Curriculum vitae Lisa Schwartz Page 4 CURRENT TEACHING RESPONSIBILITIES: Dartmouth Medical School Date Teaching 2000-Present Co-Course Director, Introduction to Survey Research Methods The Dartmouth Institute for Health Policy and Clinical Practice, Masters Program 2012-Present Co-Director, Professional Development Seminar The Dartmouth Institute for Health Policy and Clinical Practice National 2002-Present Curriculum design and teacher, National Institutes of Health, Medicine in the Media: Workshop for Medical Journalists (on hold until reubudgeting approved at NCI tenatively scheduled to resume 2015) 2003-Present Workshop teacher (1/2 day session); Medical Evidence Boot Camp for Medical Journalists Knight Science Journalism Fellowships at Massachusetts Institute of Technology INVITED PRESENTATIONS SELECTED RECENT PRESENTATIONS: Date Topic Organization Location 2009 The effectiveness of the drug FDA, Risk Communication facts box in communicating Advisory Committee the benefits and side effects of prescription drugs Washington, DC 2009 Know your chances: A curriculum to help students become better consumers of statistics 2009 Helping journalists effectively National Press Club communicate the results of medical research Washington, DC 2009 How might SEER make smarter journalists, physicians and patients? SEER Visioning Exercise National Cancer Institute Bethesda, MD 2010 Communicating the benefits and harms of prescription drugs Medical Grand Rounds Minneapolis VA Medical Center Minneapolis, MN 2010 A randomized trial about communicating numbers and cautions National Center Institute Division of Cancer Prevention Rockville, MD 2010 Breast cancer and the media: Who gets it right? National Breast Cancer Coalition Washington DC National Meeting of the American Washington, DC Statistical Association Curriculum vitae Lisa Schwartz Page 5 2010 The drug facts box: Communicating the benefits and harms of prescription drugs Evidence 2010 British Medical Journal London, UK 2011 The drug facts box: National Health Service Choices London, UK 2011 The drug facts box Center for Medicaid and Medicare Baltimore, MD Services 2011 Bad news and good news National Cancer Institute Prevention Fellows Bethesda, MD 2011 Understanding the facts when reporting on breast cancer National Breast Cancer Coalition New York, NY 2012 Generating the science needed National Academy of Sciences for relevant communication Washington, DC 2013 "Continuish" outcomes JAMA/BMJ Peer Review Congress Chicago, IL 2013 Overdiagnosis (plenary) Cochrane Collaboration Oxford, UK 2013 Making sense of medical information New England Association of Medical Librarians Woodstock, NY 2014 Overdiagnosis (plenary) Israeli National Association of Family Physicans Tel Aviv, Israel 2014 Communicating uncertainty IOM/FDA about the benefits and harms of pharmaceutical products Silver Spring, MD Media analysis: Tysabri case study 2014 Communicating uncertainty about new drugs AAAS/Brigham & Women's Hospital Washington, DC 2015 FDA and the media: Lessons from Tysabri IOM Drug Forum Washington, DC Curriculum vitae Lisa Schwartz Page 6 MAJOR RESEARCH INTERESTS My research addresses the excessive fear and hope created by exaggerations, distortions, and selective reporting in medical journals, advertising, and health news. My goal is to improve the communication of medical evidence about cancer screening and prescription drugs to physicians, journalists, and the public. Together with the NIH, I have run the health journalist workshop “Medicine in the Media: The challenges of reporting on medical research” for the past 11 years and organized the first scientific conference on Overdiagnosis held at Dartmouth (co-sponsored by Dartmouth, BMJ and Consumer Reports), co-authored 2 books: Know Your Chances (selected for the NLM bookshelf) and Overdiagnosed. I have collaborated with the FDA's Center for Drug Evaluation and Research to develop better prescription drug information and the National Cancer Institute to develop better presentations of cancer statistics. RESEARCH FUNDING: 1. Enhancing informed decision making about mammography (1996-2001), Department of Defense Breast Cancer Research Program, New Investigator Award (4 years), (Joint principal investigator) 2. Department of Veterans Affairs Health Services Research & Development (Level I), Career Development Award (1998-2001) Full salary support (Principal investigator) 3. Understanding numbers and health: A primer for patients (2000-2005), R18 National Cancer Institute (2 years) (Joint principal investigator) 4. Department of Veterans Affairs Health Services Research & Development, Advanced Career Development Award (2002-2005) Full salary support (Principal investigator) 5. Volume matters: Helping patients pick hospitals. R03 AHRQ (2002-2003) (Co-principal investigator) 6. Simple tools to facilitate risk communication in primary care, Robert Wood Johnson Generalist Faculty Scholar Program (2002-2006) (Principal investigator) 7. Center to address harm from medical care, VA HSR&D REAP Application (4/03-9/08) (Coinvestigator) 8. Helping physicians critically evaluate drug information: A curriculum and method for enhancing sensible decision making during office visits, State of Oregon, Prescriber and Consumer Education Grant (7/06-6/09) (Joint principal investigator) 9. Improving the quality of news media reporting on medicine, R01 NIH (7/04-6/10) (Joint principal investigator) 10. The prescription drug facts box. Robert Wood Johnson Pioneer Program (8/08-2/12) (Joint Principal Investigator) 11. .Incidence of pulmonary nodules and downstream resource use in the VA. VA Health Services Research & Development Merit Review (10/08-6/12). Principal Investigator: Curriculum vitae Lisa Schwartz Page 7 Steven Woloshin, Co-Principal Investigator: Renda Wiener. Co-Investigator: Lisa M. Schwartz. 12. Bringing drug facts boxes to the public: Developing a self-sustaining model. Robert Wood Johnson Pioneer Program (11/11 – 4/13) ) (Joint Principal Investigator) 13. Making drug facts boxes available to the public through a self-sustaining business model Robert Wood Johnson Pioneer Program (12/12 – 11/13 ) (Joint Principal Investigator) BIBLIOGRAPHY Original Articles 1. Woloshin S, Bickell NA, Schwartz LM, Gany F, Welch HG. Language barriers in medicine in the United States. JAMA 1995; 273: 724-728. [Response to letters: JAMA 1995; 274:684] 2. Schwartz LM, Woloshin S, Welch HG. Trends in diagnostic testing following a national guideline for evaluation of dyspepsia. Arch Intern Med 1996; 156:873-875. 3. Schwartz LM, Fisher ES, Tosteson AN, Woloshin S, Chiang CH, Plohman J, Vernig B, Wright, B. Treatment and health outcomes of women and men in a cohort with coronary artery disease. Arch Intern Med. 1997; 157: 1545-1551 4. Woloshin S, Schwartz LM, Katz S, Welch HG. Is language a barrier to the use of preventive services? J Gen Intern Med 1997; 12(8):472-7. 5. Woloshin S, Schwartz LM, Tosteson AN, Chiang CH, Wright B, Plohman J, Fisher ES. Tangible social support and health outcomes in patients with coronary artery disease. J Gen Intern Med. 1997; 12(10):613-8. 6. Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997; 127: 966-972. 7. Schwartz LM, Woloshin S, Renfrew R, Wasson JH, Welch HG. Setting the revisit interval in primary care. J Gen Intern Med 1999; 14: 230-235. 8. Welch HG, Chapko M, James, Schwartz LM, Woloshin. The role of patients and providers in the timing of follow-up visits J Gen Intern Med 1999; 14:223-229. 9. Schwartz LM, Woloshin S. Changing disease definitions: Implications on disease prevalence. Eff Clin Pract 1999; 2:76-85. 10. Woloshin S, Schwartz LM. The US Postal Service and cancer screening: Stamps of approval? N Engl J Med 1999; 340: 884-887. [Response to letters: N Engl J Med 1999; 341: 543] 11. Woloshin S, Schwartz LM, Black WC, Welch HG. Women's perceptions of breast cancer risk: How you ask matters. Med Decis Making 1999; 19: 221-229. 12. Woloshin S, Schwartz LM. How can we help patients make sense of medical data? Eff Clin Pract 1999; 2:176-183. 13. Schwartz LM, Woloshin S, Welch HG. Misunderstandings about the effect of race and sex on physicians' referrals for cardiac catheterization. N Engl J Med 1999; 341:279-283. [Response to letters: N Engl J Med 1999; 341: 2022] Curriculum vitae Lisa Schwartz Page 8 14. Schwartz LM, Woloshin S, Welch HG. Risk communication in clinical practice: Putting cancer in context. Monogr Natl Cancer Inst 1999; 25:124-33. 15. Woloshin S, Schwartz LM, Byram SJ, Sox HC, Fischhoff B, Welch HG. Women's understanding of the mammography screening debate. Arch Intern Med 2000;160:1434-1440. 16. Welch HG, Schwartz LM, Woloshin S. Are changing five year survival rates evidence of progress against cancer? JAMA 2000; 283:2975-2984. [Response to letters: JAMA 2000; 284: 2054-55. 17. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ 2000; 320:1635-1640. [Response to letters: BMJ 2000:321: 1049] 18. Reprinted: Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. West J Med 2000; 173:307-12. 19. Woloshin S, Schwartz LM, Byram SB, Fischhoff B, Welch HG. A new scale for assessing perceptions of chance: A validation study. Med Decis Making 2000;20:298-307 20. Zacharski L, Ornstein DL, Woloshin S, Schwartz LM. The association of age, sex and race with body iron stores in adults: Analysis of NHANES III Data. Am Heart J 2000;140:98-104. 21. Silverman E, Woloshin S, Schwartz LM, Byram SJ, Welch HG, Fischhoff B. Women’s Views on Breast Cancer Risk and Screening Mammography: A qualitative interview study. Med Decis Making 2001;21:231-40. 22. Woloshin S, Schwartz LM, Moncur M, Gabriel S, Tosteson ANA. Assessing values for health: Numeracy matters Med Decis Making 2001; 21:382-390. 23. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct to consumer drug advertisements: What are Americans being sold? Lancet 2001; 358:1141-6. 24. Liu JY, Woloshin S, Laycock WS, Schwartz LM. Late outcomes after laparoscopic surgery for gastroesophageal reflux. Arch Surg 2002;137:397-401. 25. Schwartz LM, Woloshin S. msJAMA-Marketing medicine to the public: A reader's guide. JAMA 2002; 287:774-775. 26. Woloshin S, Schwartz LM, Welch HG. Tobacco money: Up in smoke? Lancet 2002; 359: 2108-2111. [Response to letters: Lancet 2002;360:954] 27. Schwartz LM, Woloshin S, Baczek L. Media coverage of scientific meetings: Too much, too soon? JAMA 2002;287:2859-63 28. Woloshin S, Schwartz L. Press releases: Translating research into news. JAMA 2002;287:2856-8. 29. Woloshin S, Schwartz LM, Welch HG. Risk charts: Putting cancer in context. J Natl Cancer Inst 2002; 94:799-804. [Response to letters: J Natl Cancer Inst 2002; 94: 1585-1586.] 30. Schwartz LM, Woloshin, S. News media coverage of screening mammography for women in their forties and tamoxifen for primary prevention of breast cancer. JAMA 2002;287:3136-3142. 31. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colon cancer: Does Curriculum vitae Lisa Schwartz Page 9 practice match evidence? JAMA 2003; 289:1414-20. 32. Schwartz LM, Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004; 291:71-8. [Response to letters: JAMA 2004; 291:1836. 33. Caudhill-Slosberg M, Schwartz LM, Woloshin S. National trends in office visits and analgesic prescriptions for musculoskeletal pain: 1980 vs. 2000. Pain 2004: 109:514-19. 34. Woloshin S, Schwartz LM, Welch HG. The value of benefit data in direct-to-consumer drug ads. Health Affairs 2004: W234-245. Accompanying editorials by FDA (Peter Pitts), Senator James Jeffords, Representative Henry Waxman, Eli Lilly and Pfizer. 35. Liu J, Woloshin S, Laycock W, Rothstein, RI, Finlayson S, Schwartz LM. Validating the GERD Assessment Scales(GAS): Measuring the symptom and treatment burden of GERD. Arch Intern Med 2004; 164:2058-2064. 36. Sirovich B, Woloshin S, Schwartz LM. Screening for cervical cancer: Will women accept less? Am J Med 2005; 118:151-158. 37. Larson, R, Schwartz LM, Woloshin S, Welch HG. Advertising by Academic Medical Centers. Arch Intern Med. 2005; 165:1-7. 38. Welch HG, Schwartz LM, Woloshin S. Exaggerated relationship between diet, body weight and mortality: The case for a categorical data approach. Can Med Assn J 2005;891-95. 39. Larson, R, Schwartz LM, Woloshin S, Welch HG. Celebrity endorsements of cancer screening. J Natl Cancer Inst 2005;97:693-5. 40. Schwartz LM, Woloshin S, Welch HG. Can patients interpret health information? An assessment of the medical data interpretation test. Med Dec Making. 2005;25:290-300. 41. Welch HG, Schwartz LM, Woloshin S. Prostate specific antigen levels in the United States: Implications of various definitions for abnormal. J Natl Cancer Inst 2005; 97:1132-7. 42. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and the incidence of melanoma. population based ecological study BMJ 2005; 331:481-5. 43. Schwartz LM, Woloshin S, Birkmeyer JB. How do elderly patients decide where to go for major surgery? Telephone interview survey BMJ 2005; 331:821-4. 44. Woloshin S, Schwartz LM, Welch HG. Patients and medical statistics: Interest, confidence and ability. J Gen Intern Med 2005; 20:996-1000. 45. Woloshin S, Schwartz LM. Giving legs to restless legs: A case study of how the media helps make people sick. PLoS Med 2006 3(4) e170: 0452-0455. 46. Woloshin S, Schwartz LM. Media reporting on scientific meeting presentations: More caution needed. MJA 2006; 184(11):576-580. 47. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ 2006 333:1248-50. 48. Woloshin S, Schwartz LM, Welch HG. The effectiveness of a primer to help people understand risk: Two randomized trials in distinct populations. Ann Intern Med 2007 146:256-265 49. Wilson, CT, Woloshin, S, Schwartz LM. Choosing where to have major surgery: Who decides? Arch Surgery 2007 142:242-246. 50. Woloshin S, Schwartz LM, Kerin K, Welch HG. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States J Gen Intern Med 2007 Curriculum vitae Lisa Schwartz Page 10 22:197-204 51. Kallen AJ, Shu JA, Juhl EL, Woloshin S, Schwartz LM. Direct-to-consumer advertisements for HIV antiretroviral medications: A progress report. Health Affairs 2007 26:1392-1398. 52. Schwartz LM, Woloshin S, Welch HG. The drug facts box: Providing consumers with simple tabular data on drug benefit and harm. Med Decis Making 2007;27:655-662. 53. Herndon, MB, Schwartz LM, Woloshin S, Welch HG. Implications of expanding disease definitions: The case of osteoporosis. Health Affairs 2007; 26: 1702-1711. 54. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gotzsche PC, Harris R, Kramer BS, Ransonhoff DF. Overstating the evidence for lung cancer screening: The I-ELCAP study. Arch Intern Med 2007;167(21):1-7. 55. Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States: Putting health risks in context. J Natl Cancer Inst. 2008; 100: 845 - 853. 56. Herndon B, Schwartz LM, Woloshin S, Anthony D, Gallagher P, Fowler FJ, Fisher ES. Older patient's perceptions of "unnecessary" test and referrals: A national survey of Medicare beneficiaries. J Gen Intern Med 2008; 23:1547-54. 57. Gigerenzer G, Gaissmaier W, Kurze-Milcke Elke, Schwartz LM, Woloshin S Knowing your chances: What health stats really mean Scientific American Mind April 2009 58. Schwartz LM, Woloshin S, Welch HG. Communicating drug benefits and harms with the drug facts box: Two randomized trials. Ann Intern Med 2009 150: 516-527. 59. Woloshin S, Schwartz LM, Cassela S, Kennedy A, Larson RJ. Academic medical center press releases: Not so academic? Ann Intern Med 2009 150: 613-618 60. Wallace D, Rheinlander K, Woloshin S, Schwartz LM. Quantitative literacy assessments: An introduction to testing tests. Numeracy 2009 Iss 2, Article 3. 61. Schwartz LM, Woloshin S. Lost in transmission – FDA drug information that never reaches clinicians. N Engl J Med 2009; 361: 1717-1720. 62. Cordoba G, Schwartz LM, Wolsohin S, Bae H, Goetzsche PC. Definition, reporting and interpretation of composite outcomes in clinical trials: Systematic review. BMJ 2010 341:C3920. 63. Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis 2010;16:1658-62. 64. Wiener RS, Schwartz LM, S Woloshin. Time Trends in Pulmonary Embolism in the United States: Evidence of Overdiagnosis. Arch Intern Med 2011;171:831-837. 65. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment: A randomized trial. Ann Intern Med 2011:155:87-96. 66. Wiener R, Schwartz LM, Wolos21hin S, Welch. Population-based risk for complications after transthoracic needle lung biopsy. Ann Intern Med 2011: 155: 137-44. 67. Schwartz LM, Woloshin, S. Communicating uncertainties about prescription drugs to the public. A national randomized trial. Arch Intern Med 2011:171:1463-1468 68. Sirovich BE, Woloshin S, Schwartz LM. Too little? Too much? Primary care physicians' view on US Health Care. Arch Intern Med 2011:171:1582-1585. Curriculum vitae Lisa Schwartz Page 11 69. Schwartz LM, Woloshin S, Andrews A, Stukel TA. Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study. BMJ 2012; 344:d8164. 70. Wegwarth O, Schwartz LM, Woloshin S, Gaissmeier W, Gigerenzer G. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med 2012; 156:340-349. 71. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. "The thing is not knowing": patients' perspectives on surveillance of an indeterminate pulmonary nodule. Health Expect. 2012 doi: 10.1111/hex.12036 72. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. "What do you mean, a spot?". A qualitative analysis of patients' reactions to discussions with their doctors about pulmonary nodules. Chest 2012 doi: 10.1373/chest.12-1095. 73. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns – getting past uninformative persuasion. N Engl J Med 2012; 367:1677-1679. 74. Schwartz LM, Woloshin S. The Drug Facts Box: Improving the communication of prescription drug information, Proc Nat Acad Sci 2013 , Proc Nat Acad Sci 2013. www.pnas/cgi/doi/10.1073/pnas.1214646110 75. Wiener RS, Schwartz LM, Woloshin S. When a test is too good: How CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ 2013 346:3368 doi: 10.1136/bmj.f3368. 76. Morden, N. Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med 2013 369:229-302. 77. Woloshin S, Schwartz LM, Dann E, Black WC. Using radiology reports to encourage evidencebased practice in the evaluation of small incidentally detected pulmonary nodules: A preliminary study. Annals ATS 2013 doi 10.1513/AnnalsATS.201307-242BC 78. .Weiner RS, Gould, MK Slatore CG, Fincke BG, Schwartz LM, Woloshin S. Resource Use and Guideline Concordance in Evaluation of Pulmonary Nodules for Cancer: Too Much and Too Little Care. JAMA Intern Med 2014 Apr 7. doi: 10.1001/jamainternmed.2014.561 79. Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med 2014 Apr 1;174(4):615-9. doi: 10.1001/jamainternmed.2013.14629. 80. Howlander N, Mariotto AB, Woloshin S, Schwartz LM. Providing clinicians and patients with actual prognosis: Cancer in the context of competing causes of death. J Natl Cancer Inst (Survival Monograph) 2014;49:255-264. 81. Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst (Survival Monograph) 2014. 49:187-197. 82. Mariotto AB, Noone A, Howlander N, Cho H, Woloshin S, Schwartz LM. Cancer Survival: An overview of measures, uses and interpretation J Natl Cancer Inst (Survival Monograph) 2014:49:145-186. 83. Woloshin S, Schwartz LM, Frankel B, Faerber A. FDA and the design of drug approval studies. Curriculum vitae Lisa Schwartz Page 12 JAMA 2014: 312: 263-265. 84. Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015 38:565-75 85. Simmons J, Gould MK, Woloshin S, Schwartz LM, Wiener RS. Attitudes about low-dose computed tomography screening for lung cancer: a survey of American Thoracic Society Clinicians. Am J Resp Crit Care Med 2015 191:483-6. BMJ Occasional Column: Not So Stories 1. Schwartz LM, Woloshin S. How the FDA forgot the evidence: The case of donepezil 23mg. BMJ 2012;344:e1086 2. Woloshin S, Schwartz LM. How a charity oversells mammography. BMJ 2012;345:e5132. Monograph 1. Gigerenzer G, Gaissmaier W, Kurze-Milcke Elke, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. Psychological Science in the Public Interest (A journal of the Association for Psychological Science) 2008; Vol 8. Editorials 1. Schwartz LM, Woloshin S. Patient decision making: In search of good decisions. Eff Clin Pract 1999; 2:184. 2. Schwartz LM, Woloshin S. Are health-oriented stamps bad medicine?. Physician's Weekly Vol. XVI, No.27, July 19, 1999 3. Woloshin S, Schwartz LM Early stage breast cancer treatment for elderly women: Does one size fit all? Surgery 2000; 128:865-7. 4. Schwartz LM, Woloshin S. The case for letting information speak for itself. Eff Clin Pract 2001; 4:76-79. 5. Woloshin S, Schwartz LM. Smoke-free movies: sense or censorship?. Eff Clin Pract 2002; 5:29-30. 6. Schwartz LM, Woloshin S. On the prevention and treatment of exaggeration. J Gen Intern Med 2003; 18: 153-154. 7. Woloshin S, Schwartz LM, Ellner A. Making sense of risk information on the web: Don't forget the basics. BMJ 2003. 327:695-6. 8. Schwartz LM, Woloshin S. The media matters: A call for straightforward medical reporting Ann Intern Med 2004; 140: 226-228. 9. Woloshin S, Schwartz LM. Reducing the risk that patients get it wrong. Gastroenterology 2005; 129:748-50. 10. Woloshin S, Schwartz LM. What's the rush? The dissemination and adoption of preliminary research findings. J Natl Cancer Inst 2006; 98:372-373. 11. Schwartz LM, Woloshin S. Participation in mammography screening. BMJ 2007; 335:731-2. Curriculum vitae Lisa Schwartz Page 13 12. Welch HG, Woloshin S, Schwartz LM. The sea of uncertainty surrounding DCIS: The price of screening mammography. J Natl Cancer Inst 2008; 100:228-229. 13. Schwartz LM, Woloshin S, Moynihan R. Who's watching the watchdogs: Medical journalism and entanglement. BMJ 2008;337:a2535 14. Woloshin S, Schwartz LM. Numbers needed to decide. J Natl Cancer Inst 2009; 10:1163-65. 15. Woloshin S, Schwartz LM, Kramer BS. Promoting healthy skepticism in the news: Helping journalists get it right. J Natl Cancer Inst 2009; 101: 1596-1599. 16. Woloshin S, Schwartz LM. Bringing FDA's information to market. Arch Intern Med 2009;169: 1985-1987. 17. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: Understanding the tradeoffs. JAMA 2010 303: 164-5. 18. Schwartz LM, Woloshin S, Welch HG. Not so silver lining. Arch Intern Med 2011:171:489490. 19. Woloshin S, Schwartz LM. Getting to better prescription drug information J Gen Intern Med. 2012 27: 1582-4. 20. Moynihan R, Glasziou P, Woloshin S, Schwartz LM, Santa J, Godlee F. Winding back the harms of too much medicine. BMJ 2013 346:f1271/bmj.f1271 21. Schwartz LM, Woloshin S. Low “T” as in Template: How to Sell Disease JAMA-Intern Med. 2013 173:1460-2. 22. Schwartz LM, Woloshin S. Medical communication companies and continuing medical education: Clouding the sunshine? JAMA. 2013 310: 2507-2508. 23. Brodersen J, Schwartz LM, Woloshin S. Overdiagnosis: How cancer screening can turn indolent pathology into illness. APMIS 2014 doi: 10.1111/apm.12278. 24. Schwartz LM, Woloshin S. Men's health weak? Evidently Cochrane (http://www.evidentlycochrane.net/testosterone/) Book 1. Woloshin, S, Schwartz LM, Welch HG. Know your chances: Understanding health statistics. University of California Press (November 2008). Selected for the NLM bookshelf /PubMed Health. 2. Welch HG, Schwartz LM, Woloshin S. Overdiagnosis: How the pursuit of health can make you sick. Beacon Press (January 2011) Book Chapters 1. Moynihan R, Schwartz LM, Woloshin S. Medicine/s and the media: Good information or misleading hype. In British Medical Journal publication "Evaluating pharmaceuticals for Health Curriculum vitae Lisa Schwartz Page 14 Policy and Reimbursement. Edited by N. Freemantle, S. Hill., Blackwell Publishing Ltd, Oxford, UK. 2004. 2. Byram SJ, Schwartz LM, Woloshin S, Fischhoff B. Women's beliefs about breast cancer risk factors: A mental models approach. In Rationality and social responsibility: Essays in honor of Robyn Mason Dawes. Edited by J. Krueger. Psychology Press. 2008 3. Woloshin S, Schwartz LM. Helping consumers understand the benefits and harms of prescription drugs. In "Shared decision making in health care: achieving evidence based patient choice, 2nd edition" by Adrian Edwards and Glyn Elwyn. Oxford University Press. 2009. 4. Schwartz LM, Woloshin S. The drug facts box: Making informed decisions about prescription drugs possible. In "Better doctors, better patients, better decisions: Envisioning health care 2020" Edited by G Gigerenzer, M Gray. Strungmann Forum Report, Volume 6 MIT Press (Cambridge, MA) Publications in the Lay Media 1. Woloshin S, Schwartz LM. We should stamp out this medical misinformation. Los Angeles Times June 28, 1999, page A15. 2. Woloshin S, Schwartz LM, Welch, HG. Healthy Skepticism (occasional column): Where the naproxen story went wrong. Washington Post February 1, 2005 page E1. (http://www.washingtonpost.com/wp-dyn/articles/A52625-2005Jan31.html) 3. Schwartz LM, Woloshin S, Welch HG. Healthy Skepticism (occasional column): Overstating the benefit of aspirin for breast cancer. Washington Post. May 10, 2005, page F1, F4 4. Woloshin S, Schwartz LM. What's needed on prescription labels. The Boston Globe April 21, 2005, page A23. (Reprinted in the Valley News (4/29/05), Union Leader (5/2/05). 5. Woloshin S, Schwartz LM, Welch HG. Survival is the wrong statistics to track "War on Cancer". The Cancer Letter, July 29, 2005, page 6-7. 6. Woloshin S, Schwartz LM, Welch HG. Warned, but worse off. The New York Times. August 22, 2005, page A13. 7. Woloshin S, Schwartz LM, Welch HG. Healthy Skepticism (occasional column): A shot of fear. Washington Post. October 25, 2005, pages F1, F4. 8. Welch HG, Schwartz LM, Woloshin S. What’s making us sick is an epidemic of diagnoses. New York Times January 2, 2006, page D5. 9. Schwartz LM, Woloshin S, Welch HG. Healthy Skepticism (occasional column): Fat or fiction. Washington Post. March 14, 2006, page F1, F4 10. Welch HG, Woloshin S, Schwartz LM. Why two studies on cancer screening led to two different results. New York Times March 13, 2007. page F5, F8 11. Welch HG, Schwartz LM, Woloshin S. Finding more cancer isn’t the answer. Washington Post Curriculum vitae Lisa Schwartz Page 15 April 10, 2007. page F2. 12. Welch HG, Woloshin S, Schwartz LM. Healthy Skepticism. Boston Globe January 1, 2008, p. A13. 13. Woloshin S, Schwartz LM. Does prostate screening make sense for you? The Boston Globe, September 29, 2008. p.A11, A13. 14. Woloshin S, Schwartz LM. The EARLY Act is not what the doctor ordered. Los Angeles Times. July 31, 2009. 15. Woloshin S, Schwartz LM. Think inside the box. New York Times. July 5, 2011. Op-Ed A21. 16. Schwartz LM, Woloshin S. Endless screenings don't bring everlasting health. New York Times. April 16, 2012. Science Times D5. 17. Woloshin S, Schwartz LM. 'Low T' and the peril of medicating grumpy old men. The Los Angeles Times. February 26 2014 18. Woloshin S, Schwartz LM. Sell a disease to sell a drug. Op-Ed. Washington Post June 7, 2015